RVTY Stock Chart & Stats
$1910.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1910.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,644.85 - $2,235.19
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$235.57B
Enterprise Value$15.02K
Total Cash (Recent Filing)$1.02B
Total Debt (Recent Filing)$3.34B
Price to Earnings (P/E)59.2
Beta-0.08
Next Earnings
Nov 02, 2026EPS Estimate
21.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.10
Shares Outstanding111,586,400
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-3.41
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,141.50Price Target Upside12.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)90.58
Revenue Forecast (FY)$48.23B
Bulls Say, Bears Say
Bulls Say
Diagnostics GrowthDiagnostics is showing strong, broad-based demand across reproductive health and immunodiagnostics, providing a durable growth engine within Revvity. Continued strength in these workflows can support recurring testing activity, consumables demand, and better portfolio balance against softer research markets.
Cash Generation And DeleveragingStrong free cash flow and improving leverage give Revvity financial flexibility to fund innovation, integrate acquisitions, and reduce debt. High cash conversion also strengthens resilience through laboratory spending cycles, while fixed-rate debt and a low weighted average rate reduce financing volatility.
High-content Screening DemandDouble-digit order growth and a multi-year-high backlog indicate improving customer demand for Revvity’s high-content screening platforms. A larger installed base can create follow-on opportunities for consumables, software, and services, supporting recurring revenue beyond initial instrument sales.
Bears Say
Software Revenue VolatilityThe sharp Signals decline shows that software revenue remains sensitive to contract timing and prior-year comparisons, making growth less predictable. Although management expects recovery in the second half, uneven software performance can disrupt revenue visibility and complicate margin and investment planning.
Margin Compression And Earnings VolatilityRevvity’s current profitability is solid but remains below prior-cycle levels, while the historical net loss highlights earnings volatility. Sustained margin compression would limit operating leverage and reduce the cash available for research, acquisitions, debt reduction, and shareholder returns.
Challenging China Immunodiagnostics MarketThe planned divestiture signals that China immunodiagnostics has become a structurally difficult part of the portfolio rather than a temporary weakness. Until closing, the business remains in reported results, while the eventual exit may reduce geographic exposure and revenue scale in that market.
Revvity News
RVTY FAQ
What was Revvity’s price range in the past 12 months?
Revvity lowest stock price was $1644.85 and its highest was $2235.19 in the past 12 months.
What is Revvity’s market cap?
Revvity’s market cap is $235.57B.
When is Revvity’s upcoming earnings report date?
Revvity’s upcoming earnings report date is Nov 02, 2026 which is in 48 days.
How were Revvity’s earnings last quarter?
Revvity released its earnings results on Aug 04, 2026. The company reported $23.945 earnings per share for the quarter, beating the consensus estimate of $20.617 by $3.329.
Is Revvity overvalued?
According to Wall Street analysts Revvity’s price is currently Undervalued.
Does Revvity pay dividends?
Revvity does not currently pay dividends.
What is Revvity’s EPS estimate?
Revvity’s EPS estimate is 21.99.
How many shares outstanding does Revvity have?
Revvity has 111,586,400 shares outstanding.
What happened to Revvity’s price movement after its last earnings report?
Revvity reported an EPS of $23.945 in its last earnings report, beating expectations of $20.617. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Revvity?
Currently, no hedge funds are holding shares in MX:RVTY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2,141.50 (12.12% Upside)
$2,141.50 (12.12% Upside)
Blogger Sentiment
Neutral
MX:RVTY Sentiment 75%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.48%
12-Months-Change
Fundamentals
Return on Equity
0.22%
Trailing 12-Months
Asset Growth
-2.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Revvity
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
RVTY Company Deck
RVTY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and financial picture: revenue and EPS beat with upgraded full-year guidance, strong Diagnostics performance, accelerating high-content instrument orders and robust cash flow and balance sheet improvements. Key near-term weaknesses include a sizable decline in Signals software revenue this quarter, some production/timing constraints that shifted instrument revenue into Q3, and portions of the quarter's outperformance tied to one-time tariff refunds and tax timing. Management plans reinvestments of a portion of one-time benefits while highlighting new software capabilities and AI-driven demand as multi-year growth drivers—though the AI opportunity is still early and not fully quantifiable.View all MX:RVTY earnings summariesRVTY Revenue Breakdown
50.11% Life sciences
49.89% Diagnostics
RVTY Stock 12 Month Forecast
Average Price Target
$2,141.50
▲(12.12% Upside)